Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Hiroyuki Takamatsu, Takeshi Yamashita, Shingo Kurahashi, Takayuki Saitoh, Tadakazu Kondo, Takeshi Maeda, Hideyuki Nakazawa, Makoto Murata, Tomoko Narita, Junya Kuroda, Hisako Hashimoto, Koji Kawamura, Toshihiro Miyamoto, Sumihisa Honda, Tatsuo Ichinohe, Yoshiko Atsuta, Kazutaka Sunami

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Conventional cytogenetic analyses and fluorescent in situ hybridization (FISH) are helpful for stratifying patients with multiple myeloma (MM) into high-risk [t(4;14), t(14;16), and/or del 17p] and standard-risk [t(11;14)] categories. However, the prognosis of patients with MM treated with autologous stem cell transplantation (ASCT) stratified according to these categories remains unclear. This retrospective observational study analyzed 97 patients with MM who received a single, planned ASCT after treatment with 200 mg/m 2 melphalan between 2001 and 2011. The patients were grouped according to chromosomal abnormality, including t(11;14) (n = 45), t(4;14) (n = 31), del 17p (n = 10), t(11;14) with del 17p (n = 7), and t(4;14) with del 17p (n = 4). Median overall survival (OS) of the t(11;14) group (64.1 months) was not significantly different from that of the t(4;14) group (not reached), but it was significantly longer than that of the del 17p group (23.0 months; P =.002). G-banding revealed that the median OS of the t(11;14) group with additional chromosomal abnormalities (ACAs) (46.2 months) was significantly shorter than that of the t(11;14) group without ACAs (not reached; P =.005) and the t(4;14) group (not reached; P =.010). These findings highlight the importance of G-banding in patients with t(11;14) MM.

Original languageEnglish
Pages (from-to)474-479
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume25
Issue number3
DOIs
Publication statusPublished - Mar 1 2019

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Chromosome Aberrations
Melphalan
Survival
Cytogenetic Analysis
Fluorescence In Situ Hybridization
Observational Studies
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. / Takamatsu, Hiroyuki; Yamashita, Takeshi; Kurahashi, Shingo; Saitoh, Takayuki; Kondo, Tadakazu; Maeda, Takeshi; Nakazawa, Hideyuki; Murata, Makoto; Narita, Tomoko; Kuroda, Junya; Hashimoto, Hisako; Kawamura, Koji; Miyamoto, Toshihiro; Honda, Sumihisa; Ichinohe, Tatsuo; Atsuta, Yoshiko; Sunami, Kazutaka.

In: Biology of Blood and Marrow Transplantation, Vol. 25, No. 3, 01.03.2019, p. 474-479.

Research output: Contribution to journalArticle

Takamatsu, H, Yamashita, T, Kurahashi, S, Saitoh, T, Kondo, T, Maeda, T, Nakazawa, H, Murata, M, Narita, T, Kuroda, J, Hashimoto, H, Kawamura, K, Miyamoto, T, Honda, S, Ichinohe, T, Atsuta, Y & Sunami, K 2019, 'Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation', Biology of Blood and Marrow Transplantation, vol. 25, no. 3, pp. 474-479. https://doi.org/10.1016/j.bbmt.2018.11.003
Takamatsu, Hiroyuki ; Yamashita, Takeshi ; Kurahashi, Shingo ; Saitoh, Takayuki ; Kondo, Tadakazu ; Maeda, Takeshi ; Nakazawa, Hideyuki ; Murata, Makoto ; Narita, Tomoko ; Kuroda, Junya ; Hashimoto, Hisako ; Kawamura, Koji ; Miyamoto, Toshihiro ; Honda, Sumihisa ; Ichinohe, Tatsuo ; Atsuta, Yoshiko ; Sunami, Kazutaka. / Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2019 ; Vol. 25, No. 3. pp. 474-479.
@article{c1724035aa294174972617d75541b2de,
title = "Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation",
abstract = "Conventional cytogenetic analyses and fluorescent in situ hybridization (FISH) are helpful for stratifying patients with multiple myeloma (MM) into high-risk [t(4;14), t(14;16), and/or del 17p] and standard-risk [t(11;14)] categories. However, the prognosis of patients with MM treated with autologous stem cell transplantation (ASCT) stratified according to these categories remains unclear. This retrospective observational study analyzed 97 patients with MM who received a single, planned ASCT after treatment with 200 mg/m 2 melphalan between 2001 and 2011. The patients were grouped according to chromosomal abnormality, including t(11;14) (n = 45), t(4;14) (n = 31), del 17p (n = 10), t(11;14) with del 17p (n = 7), and t(4;14) with del 17p (n = 4). Median overall survival (OS) of the t(11;14) group (64.1 months) was not significantly different from that of the t(4;14) group (not reached), but it was significantly longer than that of the del 17p group (23.0 months; P =.002). G-banding revealed that the median OS of the t(11;14) group with additional chromosomal abnormalities (ACAs) (46.2 months) was significantly shorter than that of the t(11;14) group without ACAs (not reached; P =.005) and the t(4;14) group (not reached; P =.010). These findings highlight the importance of G-banding in patients with t(11;14) MM.",
author = "Hiroyuki Takamatsu and Takeshi Yamashita and Shingo Kurahashi and Takayuki Saitoh and Tadakazu Kondo and Takeshi Maeda and Hideyuki Nakazawa and Makoto Murata and Tomoko Narita and Junya Kuroda and Hisako Hashimoto and Koji Kawamura and Toshihiro Miyamoto and Sumihisa Honda and Tatsuo Ichinohe and Yoshiko Atsuta and Kazutaka Sunami",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.bbmt.2018.11.003",
language = "English",
volume = "25",
pages = "474--479",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

AU - Takamatsu, Hiroyuki

AU - Yamashita, Takeshi

AU - Kurahashi, Shingo

AU - Saitoh, Takayuki

AU - Kondo, Tadakazu

AU - Maeda, Takeshi

AU - Nakazawa, Hideyuki

AU - Murata, Makoto

AU - Narita, Tomoko

AU - Kuroda, Junya

AU - Hashimoto, Hisako

AU - Kawamura, Koji

AU - Miyamoto, Toshihiro

AU - Honda, Sumihisa

AU - Ichinohe, Tatsuo

AU - Atsuta, Yoshiko

AU - Sunami, Kazutaka

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Conventional cytogenetic analyses and fluorescent in situ hybridization (FISH) are helpful for stratifying patients with multiple myeloma (MM) into high-risk [t(4;14), t(14;16), and/or del 17p] and standard-risk [t(11;14)] categories. However, the prognosis of patients with MM treated with autologous stem cell transplantation (ASCT) stratified according to these categories remains unclear. This retrospective observational study analyzed 97 patients with MM who received a single, planned ASCT after treatment with 200 mg/m 2 melphalan between 2001 and 2011. The patients were grouped according to chromosomal abnormality, including t(11;14) (n = 45), t(4;14) (n = 31), del 17p (n = 10), t(11;14) with del 17p (n = 7), and t(4;14) with del 17p (n = 4). Median overall survival (OS) of the t(11;14) group (64.1 months) was not significantly different from that of the t(4;14) group (not reached), but it was significantly longer than that of the del 17p group (23.0 months; P =.002). G-banding revealed that the median OS of the t(11;14) group with additional chromosomal abnormalities (ACAs) (46.2 months) was significantly shorter than that of the t(11;14) group without ACAs (not reached; P =.005) and the t(4;14) group (not reached; P =.010). These findings highlight the importance of G-banding in patients with t(11;14) MM.

AB - Conventional cytogenetic analyses and fluorescent in situ hybridization (FISH) are helpful for stratifying patients with multiple myeloma (MM) into high-risk [t(4;14), t(14;16), and/or del 17p] and standard-risk [t(11;14)] categories. However, the prognosis of patients with MM treated with autologous stem cell transplantation (ASCT) stratified according to these categories remains unclear. This retrospective observational study analyzed 97 patients with MM who received a single, planned ASCT after treatment with 200 mg/m 2 melphalan between 2001 and 2011. The patients were grouped according to chromosomal abnormality, including t(11;14) (n = 45), t(4;14) (n = 31), del 17p (n = 10), t(11;14) with del 17p (n = 7), and t(4;14) with del 17p (n = 4). Median overall survival (OS) of the t(11;14) group (64.1 months) was not significantly different from that of the t(4;14) group (not reached), but it was significantly longer than that of the del 17p group (23.0 months; P =.002). G-banding revealed that the median OS of the t(11;14) group with additional chromosomal abnormalities (ACAs) (46.2 months) was significantly shorter than that of the t(11;14) group without ACAs (not reached; P =.005) and the t(4;14) group (not reached; P =.010). These findings highlight the importance of G-banding in patients with t(11;14) MM.

UR - http://www.scopus.com/inward/record.url?scp=85059044521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059044521&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.11.003

DO - 10.1016/j.bbmt.2018.11.003

M3 - Article

C2 - 30423479

AN - SCOPUS:85059044521

VL - 25

SP - 474

EP - 479

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -